Oberklaid–Danks Syndrome

Oberklaid–Danks syndrome, which is the original/alternate name for Bohring–Opitz syndrome (BOS)—a very rare genetic condition first separated from “Opitz C-like” presentations in the late 1990s and commonly caused by new (de novo) changes in the ASXL1 gene. Where possible, I anchor key facts to high-quality medical sources. NCBI+2Nature+2

Oberklaid–Danks syndrome—far more commonly called Bohring–Opitz syndrome (BOS)—is a very rare genetic condition that starts at birth. Most known cases are caused by new (de novo) changes in the ASXL1 gene. Children typically show a recognizable facial appearance and a characteristic body posture (bent elbows and wrists with the hands angled outward), along with feeding difficulty, poor growth, developmental delay or intellectual disability, and sometimes seizures. Other problems can include recurrent chest infections, sleep apnea, heart or kidney differences, and (rarely) Wilms tumor in childhood. Diagnosis is confirmed by genetic testing. Management focuses on careful monitoring and supportive, multidisciplinary care—there is no single “curative” drug at present. NCBI+2NCBI+2

Oberklaid–Danks syndrome (Bohring–Opitz syndrome) is a genetic condition present from birth. It affects growth and development in many body systems. Babies often have feeding problems, slow weight gain, and distinctive facial features. Many children have strongly bent elbows and wrists with ulnar-deviated fingers in early life (“BOS posture”), developmental delay, and intellectual disability. Some children also have seizures, sleep apnea, and recurrent lung infections; a small number develop Wilms tumor (a childhood kidney cancer), so screening is often advised. Most cases are caused by new changes in the ASXL1 gene that alter how DNA is packaged and read in cells (chromatin remodeling), changing normal development. MedlinePlus+2National Organization for Rare Disorders+2

Other names

This condition has been described in the literature under several names. Knowing these helps when searching medical records or research papers:

• Bohring–Opitz syndrome (BOS)

• Oberklaid–Danks syndrome

• Opitz trigonocephaly–like syndrome (historical usage)

• C-like syndrome / Opitz C-like syndrome

• BOPS (abbreviation used by patient groups and papers)

All of these terms refer to the same rare clinical entity; “Bohring–Opitz syndrome” is now the most commonly used name. NCBI+2MedlinePlus+2

Types

There is no official set of clinical “subtypes,” but doctors and researchers sometimes refer to practical groupings you may see in reports:

1. Classic BOS (Oberklaid–Danks) — the typical face, BOS posture in infancy, feeding difficulty, developmental delay. Nature

2. Molecularly confirmed BOS (ASXL1-positive) — a pathogenic or likely pathogenic variant in ASXL1. NCBI

3. Mosaic BOS — the ASXL1 change is present in a fraction of cells (child or transmitting parent), which can modify severity. MedlinePlus

4. BOS-like / atypical presentations — children with many BOS features but unusual findings (for example, refractory neonatal hypoglycemia) or evolving features; genetics may still show ASXL1 or remain unsolved. pediatr-neonatol.com+1

The name “Oberklaid–Danks” persists historically because early cases were described by F. Oberklaid and D. M. Danks; the consolidated entity was later named Bohring–Opitz syndrome. NCBI

Causes

In BOS, “cause” means how the ASXL1 gene is damaged and how that damage leads to the condition. Almost all are genetic, usually new in the child.

1. ASXL1 loss-of-function (haploinsufficiency). One working copy of the gene is not enough for normal development. NCBI

2. De novo (new) mutation in ASXL1. The change arises in the egg/sperm or very early embryo; parents are typically unaffected. MedlinePlus

3. Nonsense variants. A “stop” signal truncates the protein early. NCBI

4. Frameshift variants. Small insertions/deletions shift the reading frame and truncate the protein. NCBI

5. Splice-site variants. Disrupt mRNA splicing so exons are skipped or misjoined. NCBI

6. Exonic deletions/duplications involving ASXL1. Larger structural changes removing or duplicating coding segments. NCBI

7. Chromosomal microdeletions including 20q11.21 (ASXL1 locus). Rare copy-number losses that remove ASXL1. bohring-opitz.org

8. Parental gonadal mosaicism. A clinically healthy parent carries the ASXL1 change in some egg/sperm cells, allowing recurrence in siblings. MedlinePlus

9. Post-zygotic mosaicism in the child. The mutation occurs after fertilization, so only some tissues carry it, sometimes altering severity. MedlinePlus

10. Nonsense-mediated decay of ASXL1 mRNA. Truncating variants trigger degradation of the message, lowering protein levels. NCBI

11. Disrupted chromatin remodeling. ASXL1 helps control how DNA is packaged; disruption alters gene expression during development. MedlinePlus

12. Dysregulation of developmental gene programs. Broad downstream effects on growth and organ formation result from chromatin changes. (Mechanistic summary from reviews.) Wiley Online Library

13. Embryonic growth pathway disturbance. Explains intrauterine growth restriction and early feeding failure in many infants. Orpha.net

14. Neurological developmental pathway effects. Contributes to hypotonia, delay, and seizures in some children. MedlinePlus

15. Craniofacial development effects. Explains trigonocephaly in a subset and typical facial configuration. MedlinePlus

16. Skeletal/limb patterning effects. Underlie BOS posture and joint contractures in infancy. Nature

17. Autosomal-dominant inheritance pattern (theoretical). If an affected adult had children, each child would have a 50% chance; in practice, most individuals with BOS do not reproduce. MedlinePlus

18. Rare BOS without identifiable ASXL1 change (phenocopy). A small minority fit the clinical picture while testing negative with earlier methods; more advanced testing may still reveal ASXL1 or another mechanism. Nature

19. Tumor predisposition mechanism (Wilms tumor risk). Not a separate cause of BOS, but ASXL1-related dysregulation may increase kidney tumor risk in a minority, justifying surveillance. National Organization for Rare Disorders

20. Epigenetic “downstream” effects. Genome-wide expression signatures consistent with ASXL1 loss may contribute to organ-specific problems; this frames BOS as a global chromatin disorder. (Review perspective.) Wiley Online Library

No environmental, pregnancy, or parental behavior factors are known to cause BOS; it is fundamentally a genetic disorder. NCBI

Symptoms and signs

1. Poor growth before and after birth. Babies are often small at birth and gain weight slowly due to feeding difficulty and increased energy needs. Orpha.net

2. Feeding difficulty and reflux. Weak suck, aspiration risk, and vomiting are common in infancy, sometimes needing tube support. National Organization for Rare Disorders

3. BOS posture. Shoulders slouch; elbows and wrists flex; fingers deviate toward the little finger. This often softens with age. MedlinePlus

4. Distinctive facial features. May include a flat nasal bridge, anteverted nares, high-arched/cleft palate, micrognathia, low-set ears, synophrys, and a low frontal hairline. MedlinePlus

5. Eye differences and vision issues. Exophthalmos, strabismus, hypertelorism, and upslanting fissures can affect visual tracking. MedlinePlus

6. Developmental delay and intellectual disability. Most children need comprehensive therapies and educational support. MedlinePlus

7. Seizures (some children). Require EEG evaluation and individualized anti-seizure care. MedlinePlus

8. Sleep-disordered breathing (obstructive apnea). Can worsen growth and learning; sleep studies guide management. MedlinePlus

9. Recurrent respiratory infections. Aspiration and airway abnormalities increase lung infection risk. National Organization for Rare Disorders

10. Cardiac problems (in a subset). Structural or rhythm findings may be present and need cardiology evaluation. Wikipedia

11. Renal tumor risk (Wilms). Small but real risk prompts ultrasound screening in early childhood at some centers. National Organization for Rare Disorders

12. Brain differences (some). A minority show microcephaly or trigonocephaly; MRI can be normal or show anomalies. MedlinePlus

13. Hypotonia and later motor delay. Low muscle tone contributes to late milestones; PT/OT are central. Nature

14. Feeding-related aspiration (“silent” at times). Can occur without coughing; swallow studies help detect and manage. National Organization for Rare Disorders

15. Variable survival. Some children die in early childhood from heart, airway, apnea, or infection complications; others reach adolescence/early adulthood. Careful monitoring improves outcomes. MedlinePlus

Diagnostic tests

A) Physical examination (bedside assessment)

1. Growth measurements (weight, length/height, head size). Track faltering growth and microcephaly; baseline for nutrition plans. Orpha.net

2. Facial feature assessment. Helps clinicians recognize BOS and differentiate from look-alike syndromes. Nature

3. Posture and joint exam. Identifies the classic BOS posture, elbow/wrist flexion, ulnar deviation, and any contractures. Nature

4. Neurologic exam. Tone, reflexes, and movement patterns screen for seizures or motor delay needing further tests. MedlinePlus

5. Cardiorespiratory exam. Detects murmurs, breathing difficulty, aspiration signs; guides imaging and sleep testing. National Organization for Rare Disorders

B) Manual/functional tests (clinician-administered tools)

6. Feeding and swallow evaluation (speech/OT). Bedside and videofluoroscopic assessment to detect aspiration and plan safe feeding. National Organization for Rare Disorders

7. Developmental screening tools (e.g., Bayley Scales). Quantify cognitive, language, and motor delays to target therapy. Nature

8. Vision assessment (orthoptics/ophthalmology). Checks for strabismus, refractive error, and visual tracking concerns. MedlinePlus

9. Hearing evaluation. Newborn screening and follow-up (OAE/ABR) help address speech-language outcomes. (General BOS care guidance.) Wiley Online Library

10. Airway assessment by ENT. Examines for structural contributors to apnea or aspiration; informs sleep and feeding plans. National Organization for Rare Disorders

C) Laboratory & pathological tests

11. Molecular genetic testing of ASXL1 (sequencing). The key confirmatory test; looks for single-letter changes, small indels. NCBI

12. Deletion/duplication (copy-number) analysis of ASXL1. Detects exon-level losses/duplications not seen on routine sequencing. NCBI

13. Chromosomal microarray. Screens for larger 20q11.21 changes that include ASXL1 or other relevant CNVs. bohring-opitz.org

14. Targeted parental testing for mosaicism. Helps explain recurrence risk when a child has a “de novo” variant. MedlinePlus

15. Basic labs guided by symptoms (e.g., electrolytes, nutrition markers). Support management of reflux, feeding failure, and intercurrent illness. (Care reviews.) Wiley Online Library

D) Electrodiagnostic tests

16. Electroencephalogram (EEG). Evaluates seizures or suspicious events; guides anti-seizure treatment. MedlinePlus

17. Polysomnography (overnight sleep study). Confirms obstructive sleep apnea and guides CPAP/ENT interventions. MedlinePlus

18. Electrocardiogram (ECG) if indicated. Screens rhythm issues when there are symptoms or abnormal exams. (Care reviews.) Wiley Online Library

E) Imaging tests

19. Brain MRI (as clinically indicated). Looks for structural differences in children with severe delay or seizures. MedlinePlus

20. Renal ultrasound surveillance (early childhood). Some centers screen periodically for Wilms tumor due to reported risk. National Organization for Rare Disorders

Non-pharmacological treatments (therapies & other supports)

1. Early physical therapy (PT).
   Purpose: Build strength, balance, and joint range to support sitting, standing, and walking.
   Mechanism: Guided stretching and movement patterns reduce contractures, improve muscle tone and alignment, and teach safe mobility. Over time, consistent PT helps prevent secondary problems like tight tendons and hip instability that can come with limited movement in BOS. NCBI

2. Occupational therapy (OT) for daily living.
   Purpose: Make everyday activities—feeding, dressing, bathing—simpler and safer.
   Mechanism: OT adapts tasks and uses splints, special grips, and positioning to work with the BOS posture. It builds fine-motor control and suggests home equipment that saves energy and prevents joint strain. NCBI

3. Feeding therapy & safe swallowing strategies.
   Purpose: Improve nutrition and reduce choking or aspiration.
   Mechanism: A speech-language pathologist (SLP) assesses swallowing, recommends food textures, pacing, and positioning, and trains caregivers in safe techniques. This lowers the risk of lung infections linked to silent aspiration. NCBI+1

4. Nutritional support & growth monitoring.
   Purpose: Achieve steady weight gain and prevent deficiencies.
   Mechanism: Dietitians tailor calorie-dense meals, add supplements, and design schedules that fit the child’s energy level and reflux risk. Regular tracking catches faltering growth early. National Organization for Rare Disorders

5. Positioning, seating, and orthotics.
   Purpose: Support posture, comfort, and safe mobility.
   Mechanism: Custom seating, wrist/hand splints, ankle-foot orthoses, and nighttime positioning reduce the BOS flexed-wrist posture, distribute pressure, and protect joints from long-term deformity. NCBI

6. Communication therapy (speech/augmentative communication).
   Purpose: Give the child reliable ways to communicate needs.
   Mechanism: SLPs build language with signs, pictures, or speech-generating devices. Early AAC reduces frustration, supports learning, and strengthens social connection even when speech is limited. NCBI

7. Sleep apnea evaluation and support (e.g., CPAP/NIV if indicated).
   Purpose: Improve sleep quality, oxygen levels, and daytime alertness.
   Mechanism: A sleep study identifies obstructive pauses in breathing; airway positioning, oxygen, or positive pressure devices keep the airway open and reduce nighttime stress on the heart and lungs. MedlinePlus

8. Seizure safety planning & rescue training.
   Purpose: Keep the child safe during seizures and guide when to use rescue steps.
   Mechanism: Families learn positioning, triggers to avoid, and when to call emergency services. This lowers the risk of injury and prolonged seizures while medical therapy is optimized. NCBI

9. Vision and hearing services.
   Purpose: Maximize learning and safety.
   Mechanism: Regular eye and hearing checks catch treatable issues such as strabismus or refractive error. Correcting input (glasses, patches, devices) boosts development and communication. MedlinePlus

10. Reflux and aspiration prevention without medicines.
    Purpose: Reduce vomiting, discomfort, and lung complications.
    Mechanism: Upright feeding, slower flow nipples, smaller frequent meals, and post-feed positioning lower reflux and aspiration risk; a wedge or hospital bed head elevation can help at night. NCBI

11. Chest physiotherapy & airway clearance (when advised).
    Purpose: Prevent pneumonia in children prone to aspiration or weak cough.
    Mechanism: Techniques like percussion, assisted cough, and devices that mobilize mucus make breathing easier and reduce infections. NCBI

12. Developmental and educational interventions (early intervention, IEP).
    Purpose: Support learning, play, and participation.
    Mechanism: Structured goals, small-step teaching, sensory supports, and consistent routines build skills over time. National Organization for Rare Disorders

13. Orthopedic contracture management.
    Purpose: Maintain range and function.
    Mechanism: Daily home stretching, splints, and serial casting (when needed) minimize joint stiffness tied to the BOS posture. NCBI

14. Dental and oral-motor care.
    Purpose: Reduce pain, feeding difficulty, and infection.
    Mechanism: Early dental visits, fluoride, mouth-stretch exercises, and attention to palate or jaw differences help chewing and speech attempts. NCBI

15. Tumor surveillance (discuss with genetics team).
    Purpose: Detect rare Wilms tumor early.
    Mechanism: Some experts consider periodic abdominal ultrasound in early childhood for BOS; your clinical genetics team will individualize if/when to screen based on the latest evidence. NCBI+1

16. Cardiac and renal monitoring.
    Purpose: Catch structural differences early.
    Mechanism: Baseline echocardiogram, renal ultrasound, and periodic follow-up allow timely referral if issues arise. MedlinePlus

17. Behavioral supports & caregiver coaching.
    Purpose: Reduce stress and improve daily routines.
    Mechanism: Positive behavior strategies, visual schedules, and sensory regulation plans make care tasks smoother for the child and family. National Organization for Rare Disorders

18. Care coordination & social work support.
    Purpose: Connect the family with services, equipment, and financial help.
    Mechanism: A named coordinator (often in genetics or complex care) streamlines appointments and renewals so families can focus on home care. NCBI

19. Emergency plan & hospital letter.
    Purpose: Speed appropriate care during urgent illness or seizures.
    Mechanism: A concise plan lists diagnoses, airway needs, seizure rescue steps, allergies, and baseline function, so emergency teams act quickly. NCBI

20. Family mental-health support and peer networks.
    Purpose: Lower caregiver burnout and isolation.
    Mechanism: Counseling and rare-disease communities (e.g., NORD links) offer training, respite options, and practical tips from other families. National Organization for Rare Disorders

---

Drug treatments

Important note: No medicine is FDA-approved specifically for BOS. Clinicians use standard, FDA-labeled drugs to treat symptoms seen in BOS (for example, seizures, reflux, spasticity, constipation, and airway issues). Label sources below are from accessdata.fda.gov (FDA drug labels). The right medicine and dose must be individualized by the child’s clinicians.

1. Levetiracetam (antiepileptic).
   Class: SV2A-modulating antiseizure drug. Typical pediatric dosing: commonly starts ~10 mg/kg/day divided, titrated per response. Timing: twice daily. Purpose: control focal/generalized seizures reported in BOS. Mechanism: modulates synaptic vesicle protein SV2A to reduce neuronal hyperexcitability. Side effects: sleepiness, irritability, behavioral change; rarely serious mood effects—monitor closely. FDA label: accessdata.fda.gov. NCBI

2. Valproate (divalproex/valproic acid) (antiepileptic).
   Class: broad-spectrum antiseizure. Dose: individualized (often 10–15 mg/kg/day and up). Purpose: alternative for mixed seizure types. Mechanism: raises GABA, blocks sodium channels. Side effects: weight gain, tremor, liver/pancreas toxicity risk; avoid in pregnancy. FDA label: accessdata.fda.gov. NCBI

3. Clobazam (benzodiazepine antiseizure).
   Dose: low dose at bedtime up-titrated. Purpose: adjunct for refractory seizures. Mechanism: GABA-A positive allosteric modulator. Side effects: sedation, drooling, tolerance. FDA label: accessdata.fda.gov. NCBI

4. Diazepam (oral/buccal or rectal rescue).
   Purpose: home rescue for prolonged seizures per plan. Mechanism: rapid GABA-A enhancement. Side effects: drowsiness, breathing suppression if overused. FDA label: accessdata.fda.gov. NCBI

5. Omeprazole / Esomeprazole (proton pump inhibitors).
   Class: acid suppression for reflux. Dose: weight-based daily. Purpose: reduce GERD-related pain and aspiration risk. Mechanism: blocks gastric H+/K+-ATPase. Side effects: headache, diarrhea; long-term use requires monitoring. FDA label: accessdata.fda.gov. NCBI

6. Famotidine (H2 blocker).
   Purpose: alternative or step-down acid suppression. Mechanism: blocks H2 receptors on gastric parietal cells. Side effects: headache; generally well tolerated. FDA label. NCBI

7. Baclofen (oral antispastic).
   Purpose: reduce tone/contractures that limit care and comfort. Mechanism: GABA-B agonist reducing spinal reflexes. Side effects: sleepiness, weakness; taper slowly. FDA label. NCBI

8. Tizanidine (antispastic).
   Mechanism: alpha-2 agonist reducing motor neuron firing. Side effects: sedation, low blood pressure—monitor. FDA label. NCBI

9. Glycopyrrolate (anti-sialorrhea).
   Purpose: reduce drooling/aspiration risk. Mechanism: anticholinergic lowers salivary output. Side effects: constipation, dry mouth, urinary retention. FDA label. NCBI

10. Polyethylene glycol (PEG 3350).
    Purpose: constipation common in low-tone or immobile children. Mechanism: osmotic stool softener. Side effects: bloating, cramping. FDA monograph/labeling. NCBI

11. Albuterol (salbutamol) inhaler or neb.
    Purpose: relieve wheeze or reactive airways with infections. Mechanism: beta-2 bronchodilation. Side effects: tremor, fast heart rate. FDA label. NCBI

12. Budesonide (inhaled).
    Purpose: lower airway inflammation when indicated. Mechanism: corticosteroid anti-inflammatory. Side effects: oral thrush—rinse mouth. FDA label. NCBI

13. Ipratropium bromide (inhaled anticholinergic).
    Purpose: additional bronchodilation in infections. Mechanism: blocks muscarinic receptors. Side effects: dry mouth. FDA label. NCBI

14. Clonidine (sleep or tone aid under specialist care).
    Mechanism: central alpha-2 agonist improving sleep onset and, sometimes, tone. Side effects: daytime sleepiness, low BP—monitor. FDA label. NCBI

15. Melatonin (note: dietary supplement in many regions; some Rx forms FDA-approved for specific pediatric indications).
    Purpose: regulate sleep-wake cycle disrupted by apnea or neurologic issues. Mechanism: circadian signaling. Side effects: morning grogginess. Refer to product labeling; discuss with clinician. NCBI

16. Ondansetron (anti-nausea).
    Purpose: reduce vomiting that worsens feeding/aspiration risk. Mechanism: 5-HT3 blockade. Side effects: constipation, QT prolongation risk. FDA label. NCBI

17. Cyproheptadine (appetite stimulation / migraine prophylaxis).
    Mechanism: antihistamine/serotonin antagonist; sometimes helps weight gain in under-nourished children. Side effects: sedation. FDA label/history. NCBI

18. Topiramate (antiepileptic, alternative).
    Mechanism: multiple (GABA enhancement, sodium channel effects). Side effects: cognitive slowing, weight loss, kidney stones. FDA label. NCBI

19. Lamotrigine (antiepileptic, alternative).
    Mechanism: inhibits glutamate release and sodium channels. Side effects: rash (rare serious). FDA label. NCBI

20. Rescue midazolam (buccal/intranasal, per local approvals).
    Purpose: out-of-hospital rescue for clusters/prolonged seizures when prescribed. Mechanism: short-acting benzodiazepine. Side effects: sedation, respiratory depression if overdosed. FDA labeling where applicable; jurisdiction-specific. NCBI

Label note: The above drugs are FDA-labeled for the indications described (e.g., seizures, reflux, airway disease), not for BOS itself. Always use specialist guidance and official FDA labels on accessdata.fda.gov for dosing and safety in your region. NCBI

Dietary molecular supplements

(Discuss any supplement with your clinician and dietitian—needs vary, and interactions are possible.)

1. High-calorie medical formulas (energy-dense).
   Dose: As prescribed to meet daily calorie goals. Function: Improve weight gain when volume is limited. Mechanism: Concentrated calories and balanced macro/micronutrients support growth while reducing reflux-provoking volume. National Organization for Rare Disorders

2. Medium-chain triglyceride (MCT) oil.
   Dose: Small measured additions to meals. Function: Easy-to-absorb calories. Mechanism: MCTs bypass typical fat metabolism and are absorbed rapidly, helpful in poor weight gain. National Organization for Rare Disorders

3. Whey-based protein modules.
   Dose: Dietitian-directed scoops/day. Function: Support muscle growth and healing with lower gastric load. Mechanism: High biological value protein augments tissue building alongside PT. National Organization for Rare Disorders

4. Thickening agents for liquids.
   Dose: As per SLP plan. Function: Safer swallowing. Mechanism: Increases viscosity so liquids move slower, reducing aspiration. NCBI

5. Multivitamin/mineral with iron (if deficient).
   Dose: Age-appropriate daily. Function: Cover gaps from restricted diets. Mechanism: Restores micronutrients that support immunity and development. National Organization for Rare Disorders

6. Vitamin D (per labs).
   Dose: Typical pediatric maintenance 400–1000 IU/day unless deficiency needs repletion. Function: Bone and immune support, especially with limited mobility. Mechanism: Regulates calcium/phosphate and modulates immune function. National Organization for Rare Disorders

7. Omega-3 fatty acids (DHA/EPA).
   Dose: Dietitian-guided. Function: Anti-inflammatory support and general neurodevelopmental nutrition. Mechanism: Membrane incorporation and signaling effects; evidence base is general, not BOS-specific. National Organization for Rare Disorders

8. Probiotics (strain-specific).
   Dose: As advised; monitor tolerance. Function: GI comfort and stool regularity. Mechanism: Modulate gut microbiota; evidence varies by strain and condition. National Organization for Rare Disorders

9. Electrolyte rehydration solutions.
   Dose: During illness per plan. Function: Prevent dehydration from vomiting/feeding issues. Mechanism: Balanced sodium-glucose transport enhances fluid uptake. National Organization for Rare Disorders

10. Fiber supplements (soluble).
    Dose: Titrate slowly. Function: Improve stool form and reduce constipation. Mechanism: Increases stool water content and supports gut microbiome. National Organization for Rare Disorders

---

Drugs often discussed as “immunity-supporting,” regenerative, or stem-cell related

(There are no disease-modifying immune or stem-cell drugs approved for BOS. The items below explain contexts sometimes discussed in complex-care neurology/rehab; they are not BOS-specific therapies.)

1. Palivizumab (seasonal RSV prophylaxis, selected high-risk infants).
   Dose: Monthly injections during RSV season. Function/Mechanism: Monoclonal antibody lowers RSV hospitalization risk; used by criteria, not BOS-specific. NCBI

2. Influenza & routine childhood vaccines (programmatic).
   Dose: Per national schedule. Function/Mechanism: Prime immune memory to prevent severe infections—a key risk in BOS with aspiration and apnea. National Organization for Rare Disorders

3. Vitamin D (see above) as immune-modulating nutrient.
   Dose: Maintenance or repletion per labs. Function/Mechanism: Supports innate/adaptive responses and bone health. National Organization for Rare Disorders

4. Physical rehabilitation “neuroplasticity” programs.
   Dose: Ongoing blocks of PT/OT/SLP. Function/Mechanism: Repeated practice drives synaptic strengthening and motor learning; not a drug, but regenerative in aim. NCBI

5. Experimental stem-cell interventions.
   Note: Not approved for BOS; outside clinical trials they are not recommended due to risk and lack of evidence. Mechanism: Theoretical tissue repair; currently unproven for BOS. Discuss only within regulated trials. NCBI

6. Nutritional optimization as “immune booster.”
   Dose: Adequate protein, micronutrients, and calories. Function/Mechanism: Supports leukocyte function, wound healing, and resilience to infections; foundational before any medicine. National Organization for Rare Disorders

Surgeries/procedures

1. Gastrostomy tube (G-tube).
   Why done: When oral feeding is unsafe or insufficient. Procedure: Small incision places a tube into the stomach for reliable nutrition/meds. Helps growth, reduces aspiration, and eases care. NCBI

2. Fundoplication (select cases).
   Why done: Severe, refractory reflux with aspiration despite optimal therapy. Procedure: Wrap upper stomach around the esophagus to strengthen the valve and reduce reflux events. NCBI

3. Airway interventions (e.g., adenotonsillectomy; rarely tracheostomy).
   Why done: Significant obstructive sleep apnea or unsafe airway. Procedure: Remove enlarged tonsils/adenoids or create a secure airway to improve breathing and sleep. MedlinePlus

4. Orthopedic procedures (e.g., tendon releases).
   Why done: Fixed contractures that prevent hygiene, positioning, or cause pain. Procedure: Targeted soft-tissue releases with postoperative therapy to preserve gains. NCBI

5. Ophthalmologic surgery (e.g., strabismus correction).
   Why done: Improve alignment and visual development when patching/optics are not enough. Procedure: Adjust eye muscles under anesthesia. MedlinePlus

---

Prevention strategies

1. Keep up with routine vaccines and seasonal flu shots.

2. Hand hygiene and careful illness avoidance during outbreaks.

3. Safe-swallow and reflux precautions at every feed.

4. Regular PT/OT stretching to prevent contractures.

5. Dental care with fluoride and early treatment of cavities.

6. Sleep positioning and prompt evaluation for snoring/apneas.

7. Written seizure plan and access to prescribed rescue therapy.

8. Timely treatment of chest infections; consider airway clearance plans.

9. Discuss Wilms tumor surveillance with genetics team in early childhood.

10. Maintain a one-page emergency letter and updated medication list. NCBI+1

---

When to see doctors urgently

Seek urgent care for: breathing trouble, blue lips/skin, prolonged or repeated seizures, severe dehydration or inability to feed, signs of aspiration pneumonia (fever, fast breathing, wet cough), unusual abdominal swelling or blood in urine (call your team—Wilms tumor is rare but important), or any sudden change in alertness or strength. For routine care, keep regular visits with clinical genetics, neurology, pulmonology/sleep, gastroenterology/nutrition, cardiology/renal (as advised), ophthalmology, dentistry, PT/OT/SLP, and your primary pediatrician. NCBI+1

---

What to eat and what to avoid

What to eat:
• Energy-dense meals (add healthy oils/MCT per dietitian), soft/moist textures that are easier to swallow, adequate protein (dairy, eggs, poultry/legumes), fruits/vegetables well-cooked and mashed, sufficient fluids, and doctor-recommended vitamins (e.g., vitamin D, iron if low).
What to avoid or limit:
• Choking-risk foods (hard raw vegetables, nuts, tough meats) unless texture-modified; very acidic or spicy foods if reflux worsens; large volume feeds right before sleep; sweetened beverages replacing calories from balanced meals. Always follow your SLP and dietitian’s individualized texture plan. National Organization for Rare Disorders

---

Frequently asked questions (FAQs)

1) Is Oberklaid–Danks syndrome the same as Bohring–Opitz syndrome?
Yes. Oberklaid–Danks is an early name; Bohring–Opitz syndrome (BOS) is now the standard term. NCBI

2) What gene is involved?
Most cases are due to ASXL1 variants that arise de novo (not inherited from parents). NCBI

3) How is it diagnosed?
By clinical evaluation and genetic testing (typically exome or a targeted panel) that identifies an ASXL1 pathogenic variant. NCBI

4) How common is it?
Extremely rare; only a small number of cases are reported worldwide. National Organization for Rare Disorders

5) Is there a cure?
No curative drug exists yet. Care focuses on symptoms, growth, development, and preventing complications. NCBI

6) Do all children have seizures?
Not all, but seizures are relatively common and usually respond to standard anti-seizure medicines. NCBI

7) Why is feeding so difficult?
Low tone, reflux, and coordination issues raise choking/aspiration risk. Feeding therapy and, when needed, G-tubes can help. NCBI

8) What about sleep apnea?
Obstructive apnea can occur; sleep studies and airway support (e.g., CPAP) may be recommended. MedlinePlus

9) Do children outgrow the BOS posture?
The flexed-arm posture is most obvious in infancy and generally softens with age and therapy. NCBI

10) Is cancer screening needed?
A small number develop Wilms tumor; discuss individualized ultrasound screening with genetics. NCBI

11) Can my child attend school?
Yes—with individualized supports (IEP), therapies, and accessibility plans. National Organization for Rare Disorders

12) Will my child walk or talk?
Outcomes vary. Early, intensive therapy and assistive technologies improve skills and participation. NCBI

13) Is BOS inherited?
Usually de novo; recurrence risk is low but not zero (e.g., parental mosaicism). Genetic counseling is important. NCBI

14) Which specialists should we see?
Clinical genetics leads care, with neurology, pulmonology/sleep, gastroenterology, cardiology/renal, ophthalmology, dentistry, PT/OT/SLP, and primary care. NCBI

15) Where can we find support?
Organizations like NORD and rare-disease communities provide education and peer support. National Organization for Rare Disorders

Disclaimer: Each person’s journey is unique, treatment plan, life style, food habit, hormonal condition, immune system, chronic disease condition, geological location, weather and previous medical  history is also unique. So always seek the best advice from a qualified medical professional or health care provider before trying any treatments to ensure to find out the best plan for you. This guide is for general information and educational purposes only. Regular check-ups and awareness can help to manage and prevent complications associated with these diseases conditions. If you or someone are suffering from this disease condition bookmark this website or share with someone who might find it useful! Boost your knowledge and stay ahead in your health journey. We always try to ensure that the content is regularly updated to reflect the latest medical research and treatment options. Thank you for giving your valuable time to read the article.

The article is written by Team RxHarun and reviewed by the Rx Editorial Board Members

Last Updated: October 29, 2025.